Suppr超能文献

选择性雌激素受体调节剂他莫昔芬、托瑞米芬和克罗米酚在兴奋剂领域的相关性:多次口服后内源性类固醇尿液特征。

Relevance of the selective oestrogen receptor modulators tamoxifen, toremifene and clomiphene in doping field: endogenous steroids urinary profile after multiple oral doses.

机构信息

Laboratorio Antidoping, Federazione Medico Sportiva Italiana, Largo Giulio Onesti, 1, 00197 Rome, Italy.

出版信息

Steroids. 2011 Nov;76(12):1400-6. doi: 10.1016/j.steroids.2011.06.005. Epub 2011 Jun 30.

Abstract

The present study was performed to investigate the influence of the intake of selective oestrogen receptor modulators on the urinary endogenous steroids profile. For this purpose the circadian variability of luteinizing hormone, follicle-stimulating hormone, testosterone, 5α-androstan-3α,17β-diol, 5β-androstan-3α,17β-diol, epitestosterone, 4-androstenedione, androsterone and etiocholanolone were measured on eight subjects (four males and four females) by gas chromatography-mass spectrometry and chemiluminescent immunometric assay techniques before and after oral administration of multiple doses of either tamoxifen (80 mg for 2 days) or toremifene (120 mg for 2 days) or clomiphene (100 mg for 2 days). The individual baseline variability of the steroids studied was set up by collecting the urine samples every 3 h, for 3 days prior to the treatment; whereas the evaluation of the effects of the oral administration of multiple doses of selective oestrogen receptor modulators on the steroid urinary profile was assessed by collecting urine samples every three hours for at least five days from the first administration. The results of our measurements showed that, only in male subjects, the relative urinary concentrations of testosterone, epitestosterone and 4-androstenedione were significantly altered generally after the second day of drug administration. While no significant effects were recorded in both sexes on the luteinizing hormone, follicle-stimulating hormone, androsterone, etiocholanolone, 5α-androstan-3α,17β-diol and 5β-androstan-3α,17β-diol urinary levels and on testosterone/epitestosterone, 5α-androstan-3α,17β-diol/5β-androstan-3α,17β-diol and androsterone/etiocholanolone ratios.

摘要

本研究旨在探讨选择性雌激素受体调节剂(SERM)的摄入对尿内源性类固醇谱的影响。为此,通过气相色谱-质谱联用和化学发光免疫测定技术,在 8 名受试者(4 名男性和 4 名女性)中测量了促黄体生成素、卵泡刺激素、睾酮、5α-雄烷-3α,17β-二醇、5β-雄烷-3α,17β-二醇、表睾酮、4-雄烯二酮、雄酮和雄烷酮的昼夜节律变化,在口服多剂量他莫昔芬(80mg,连续 2 天)、托瑞米芬(120mg,连续 2 天)或氯米芬(100mg,连续 2 天)之前和之后。通过在治疗前收集尿液样本,每 3 小时收集一次,持续 3 天,建立了研究类固醇的个体基线变异性;通过至少在第一次给药后每 3 小时收集尿液样本 5 天,评估口服多剂量选择性雌激素受体调节剂对类固醇尿谱的影响。我们的测量结果表明,仅在男性中,在药物给药后第二天,睾酮、表睾酮和 4-雄烯二酮的相对尿浓度通常会发生显著变化。而在两性中,促黄体生成素、卵泡刺激素、雄酮、雄烷酮、5α-雄烷-3α,17β-二醇和 5β-雄烷-3α,17β-二醇的尿水平以及睾酮/表睾酮、5α-雄烷-3α,17β-二醇/5β-雄烷-3α,17β-二醇和雄酮/雄烷酮比值均无显著变化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验